Research programme: G protein-coupled receptor modulating small molecules - Omeros

Drug Profile

Research programme: G protein-coupled receptor modulating small molecules - Omeros

Alternative Names: GPR101-targeting compounds - Omeros; GPR151-targeting compounds - Omeros; GPR161-targeting compounds - Omeros; GPR17-targeting compounds - Omeros; GPR174-targeting compounds - Omeros; GPR183-targeting compounds - Omeros

Latest Information Update: 13 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Omeros Corporation
  • Class Analgesics; Antineoplastics; Antivirals; Obesity therapies; Osteoporosis therapies; Small molecules
  • Mechanism of Action G protein-coupled receptor agonists; G protein-coupled receptor antagonists; Neuromedin U receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Cognition disorders; Demyelinating disorders; Eating disorders; Epstein-Barr virus infections; Metabolic disorders; Osteoporosis; Pain
  • No development reported Autistic disorder; Gastrointestinal disorders; Inflammation; Multiple sclerosis; Obesity; Psychotic disorders; Rheumatoid arthritis; Sleep disorders

Most Recent Events

  • 13 Mar 2018 Preclinical development for Cancer and Eating disorders is ongoing in USA (Omeros pipeline, March 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Eating-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top